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AMLODIPINE AFFECtS ENDOgENOuS hyDROgEN SuLFIDE 
tISSuE CONCENtRAtIONS IN DIFFERENt MOuSE ORgANS
Abstract: Amlodipine affects endogenous hydrogen sulfide tissue concentrations in different mouse 
organs
The interactions between calcium channel blockers’ action and the endogenous hydrogen sulfide 
(h2S) biology are unknown. CBA strain mice were administered intraperitoneally 3 mg/kg b.w. per 
day or 10 mg/kg b.w. per day of amlodipine. the control group received physiological saline. the 
measurements of the free h2S tissue concentrations were performed with Siegel spectrophotometric 
modified method. There was as significant fall of H2S level in the brain and the liver in both groups. 
the lower amlodipine dose increased the h2S concentrations in the heart and kidneys while the 
higher one decreased h2S accumulation in those organs. Our experiment has shown that amlodipine 
interferes with h2S biology and affects its tissue concentrations in different mouse tissues. 
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INtRODuCtION
Hydrogen sulfide (H2S) has been identified as a crucial co-regulator of various 
physiological processes in mammals [1]. the transmitter has been also shown 
to participate in pathophysiology of different clinical disorders and is assumed 
to have some therapeutic properties as several pharmaceutical companies are 
currently under way to introduce h2S-based agents to treat various diseases [2]. 
the actions of amlodipine exceed the vasodilatation elicited by the calcium 
channel blockade and comprise i.a. the interference with cholesterol, antioxi-
dants, nitric oxide (NO) production, smooth muscle cell proliferation and ma-
trix formation [3]. the interactions of calcium channel blockers (CCBs) with the 
endogenous h2S are unknown. 
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thE AIM OF thE StuDy
The aim of the study is to assess the influence of amlodipine on the endoge-
nous tissue h2S concentrations in mouse brain, heart, liver and kidney.
MAtERIAL AND MEthODS
twenty three CBA strain female mice (11–12 weeks old individuals) of approxi-
mate 20 g weight were involved in the study. the animals were housed under 
standard laboratory conditions and had free access to water and food. they 
were kept at the temperature of 22–24°C with a light/dark cycle of 12 h. 
the study design comprised intraperitoneal injections of a solution contain-
ing amlodypine in amounts of 3 mg per kg of body weight daily (group D1, 
n = 7) or 10 mg per kg of body weight daily (group D2, n = 8) for 5 consecu-
tive days at the same time of the day (10:30 am). the third generation L-type 
CCB amlodipine (Adipine, Polfa-Rzeszów, Poland) was dissolved in a physiologi-
cal saline. Each administration comprised 0.2 mL of the solution. the control 
group (n = 8) received intraperitoneally physiological saline in portions of the 
same volume. the individuals were randomly assigned to each group. the ani-
mals tolerated the applied doses of amlodipine well and remained in a good 
condition till the end of the experiment. the measurements of the free tissue 
h2S concentrations were performed by the use of the modified method of Siegel 
[4, 5]. the study has been performed in accordance with the guidelines for the 
care and use of laboratory animals accepted by the Bioethical Committee of the 
Jagiellonian university Medical College (Kraków, Poland).
two hours after the last drug or physiological saline injection the animals 
were killed by cervical dislocation, their brains, hearts, livers and kidneys were 
quickly removed, homogenized with 0.01 mol/l sodium hydroxide (NaOH): the 
brain tissue in proportion of 1 to 4, the kidney and the liver of 1 to 5 and the 
heart of 1 to 10 and frozen. Then 50% trichloroacetic acid (TCA) was added 
(0.5 mL to 2 g of brain or liver samples in tight capsules of 3 mL and 0.25 mL 
to 1 g of heart or kidney sample in tight capsules of 2 mL), the suspension 
was shaken and centrifuged. Subsequently, 1.5 mL samples of brain or liver 
and 0.75 mL samples of heart or kidney supernatant were moved to 2 mL tight 
capsules with 0.15 mL or 0.075 mL of 0.02 mol/L N,N-dimethyl-p-phenyl-di-
amine sulfate in 7.2 mol/L hydrochloric acid (hCl), then 0.15 mL or 0.075 mL 
of 0.03 mol/L iron (III) chloride (FeCl3) in 1.2 mol/L hCl portions were added, 
respectively. After 20 minutes in darkness the content was shaken for 1 minute 
with 1 mL of chloroform. 
Absorbance was measured at 650 nm with the Varian Cary 100 spectro-
photometer. A standard curve was prepared with an iodometrically determined 
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0.0001 mol/L sodium sulfide (Na2S) solution. In all groups of the animals four 
concurrent analyses of each tissue type were performed.
the statistical analysis was performed within the R Environment by the 
Student’s t-test. Statistical significance was considered when p < 0.05.
RESuLtS
There was a significant fall in the H2S concentrations in the brain (D1 by 
26.5%, D2 by 12.9%) and in the liver (D1 by 15.6%, D2 by 31.9%) as compa-
red to the control group. the lower amlodipine dose increased the h2S tissue 
level in the heart (by 19.3%) and in the kidney (by 17.5%), while the higher 
amlodipine dose decreased the h2S contain in those organs (by 19.4% in the 
heart and by 11.6% in the kidney). The free H2S tissue concentrations’ values 
are presented in the table 1.
table 1 — tabela 1
Hydrogen sulfide (H2S) tissue concentrations in mouse brain, heart, liver and kidney 
following the administration of amlodipine in doses of 3 mg/kg b.w. per day  
or 10 mg/kg b.w. per day (groups D1 and D2 respectively)
Tkankowe stężenie siarkowodoru (H2S) w mózgu, sercu, wątrobie i nerce myszy  
po podaniu amlodypiny w dawkach 3 mg/kg masy ciała dziennie  
lub 10 mg/kg masy ciała dziennie (odpowiednio grupa D1 i D2)








Brain 1.47 ± 0.02 1.08 ± 0.02** 1.28 ± 0.03††
heart 6.89 ± 0.14 8.22 ± 0.15** 5.55 ± 0.09††
Liver 3.92 ± 0.06 3.31 ± 0.04** 2.67 ± 0.04††
Kidney 7.13 ± 0.07 8.38 ± 0.10** 6.30 ± 0.14††
Statistical significance: *p < 0.05 for Control vs D1 groups, **p < 0.01 for Control vs D1 groups,  
†p < 0.05 for Control vs D2 groups, ††p < 0.01 for Control vs D2 groups
DISCuSSION
The positive charge and high lipid affinity of amlodipine result in the drug ac-
cumulation in membranes and inhibition of modified low-density lipoproteins 
(LDLs) aggregation, mediated by electronegative properties of oxidized lipid [6]. 
Moreover, the dihydropyridine ring structure of amlodipine resides at the same 
depth as the sterol nucleus which effects in the declined ability of cholesterol 
to increase membrane width and to aggregate into crystalline-like domains. 
Elevated cholesterol content in membranes disrupts i.a. the function of Ca2+ 
32
and L-arginine transport leading to overproduction of superoxide from oxygen 
by endothelial nitric oxide synthase (eNOS), what occurs when the NO sub-
strate is lacking [3]. Amlodipine impedes this process and raises NO formation 
also with kinins’ share. As a vasorelaxant the drug elicits changes in shear 
stress, an important regulator of NO production, stimulating the formation and 
preventing the breakdown of kinins by activating and releasing kallikrein [7]. 
Furthermore, amlodipine’s R-enantiomer does not interact with the L-type cal-
cium channels but activates either angiotensin II receptors, or receptors that 
are closely related to them, stemming in augmented local kinin formation [8].
Amlodipine is a potent inhibitor of vascular smooth muscle cells prolifera-
tion. the mechanisms involve Ca2+ signaling resulting in depressed extracellular 
signal-regulated protein kinases activation (ERK1/2, MAPK), inhibition of DNA 
synthesis and expression of early growth response genes including c-myc, c-fos, 
c-jun [9, 10]. Amlodipine exerts other antioxidant activities shown to be inde-
pendent of calcium channel modulation and attributed to proton-donating and 
resonance-stabilization mechanisms that suppress free-radical reactions [11]. 
Oxidized LDLs stimulate vascular smooth muscle cells growth through activa-
tion of Ras/Raf/MEK/MAPK signaling pathway by a Pertussis toxin-sensitive 
g-protein coupled receptor, whereas amlodipine reduce the LDL oxidation proc-
ess [3, 12]. Amlodipine was also shown to inhibit metalloproteinases’ (MMPs) 
activity [13].
h2S is formed from L-cysteine in several enzymatic reactions catalyzed by 
cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE) and 3-mercapt-
opyruvate sulfurtransferase (3MST), and non-enzymatic pathways in many 
tissues [14]. Cytoplasmatic bound sulfur is postulated to absorb and store 
exogenously applied and endogenously produced h2S and release it in certain 
physiologic conditions [15]. h2S is lipophilic, freely permeates plasma mem-
branes and participates in the sulfhydration of numerous proteins which alters 
its function. Sulfhydration poses an important physiologic signal and a promi-
nent post-translational modification [16]. The action of H2S comprises numerous 
intracellular mechanisms including i.a. adenosine triphosphate (AtP)-sensitive 
potassium channels (KAtP) stimulation, maintaining protein –Sh groups in the 
reduced state, reaction with reactive oxygen and nitrogen species (ROS and 
RNS) — protection of proteins and lipids from ROS/RNS-mediated damages, 
stimulation of cysteine transport to the cell and reduced glutathione (gSh) 
synthesis, metabolic inhibition, inhibition of L-type calcium channels, an influ-
ence on ERKs, phosphoinositide 3’-kinase (PI3K)/Akt (protein kinase B), pro-
tein kinase C (PKC) and NF-E2-related factor-2 (Nrf-2) [17–22]. h2S also exerts 
some anti-inflammatory effects in certain conditions and normalizes MMP-2 
and MMP-9 activity, reduces the NF-κB complex activation and leads to fall in 
some pro-inflammatory cytokines [23–26]. Moreover, H2S interacts with carbon 
monoxide (CO) and NO in a number of ways [27].
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As we have demonstrated amlodipine in its biology interferes with the endog-
enous h2S, resulting in its altered tissue levels. the effects are dose-dependent 
and specific for each tissue what is a result of different metabolism, paracrine 
regulation and various transmitters interactions in organs. Some molecular 
aspects of amlodipine and h2S are common like L-calcium channel, NO, ERKs 
involvement, antioxidant properties or MMPs activity regulation. Experimental 
data of anti-atherosclerotic, hypotensive and anti-proliferative effects connect 
both compounds [3, 17]. the interaction mechanisms remain obscure with pro-
ba ble NO involvement as one of the link between CCB and endogenous sulfur 
biology. the h2S engagement makes the CCBs’ biology even more complex, 
pondering h2S multidirectional actions. So far it is unknown whether h2S me-
diates any of amlodipine’s effects. Interestingly, h2S bioavailability is affected 
by other drugs like aspirin, angiotensin-converting enzyme inhibitor ramipril, 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitor atorvastatin and 
paracetamol [28–32]. 
CONCLuSIONS
In conclusion, amlodipine has an impact on endogenous sulfur metabolism in 
different mouse systems, what is reflected by the free H2S tissue concentrations 
changes in different mouse organs.
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AMLODYPINA WYWIERA WPŁYW NA TKANKOWE STĘŻENIE SIARKOWODORU 
W RÓŻNYCH NARZĄDACH MYSZY
S t r e s z c z e n i e
Interakcje pomiędzy działaniem blokerów kanału wapniowego a endogennym siarkowodorem (H2S) 
nie są znane. Myszom szczepu CBA podawano dootrzewnowo wodny roztwór zawierający amlo-
dypinę w ilości 3 mg/kg masy ciała lub 10 mg/kg masy ciała dziennie. Grupa kontrolna otrzy-
mywała sól fizjologiczną. Pomiary tkankowego stężenia wolnego siarkowodoru wykonywano przy 
użyciu zmodyfikowanej spektrofotometrycznej metody Siegela. Obserwowano spadek poziomu H2S 
w mózgu i wątrobie w obydwu grupach. Niższa dawka amlodypiny powodowała wzrost stężenia H2S 
w sercu i nerkach, podczas gdy wyższa znacząco obniżała tkankowy poziom H2S w tych narzą-
dach. Wyniki naszego doświadczenia pokazują, że amlodypina ma wpływ na biologię endogennego 
siarkowodoru i powoduje zmiany w jego tkankowej koncentracji w różnych narządach myszy.
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